In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

LESSON I: Long-term comparison of Everolimus-eluting and Sirolimus-eluting Stents for coronary revascularisation

Invasive and Interventional Cardiology, Cardiovascular Surgery




Stephan Windecker, FESC
  Presenter
Presenter | see Discussant report Webcasts become available 24h after the presentation
Windecker, Stephan
(Switzerland)
Open presentation slides

List of Authors:

Abstract:

Background: Everolimus-eluting stents have improved clinical outcome compared with paclitaxel-eluting stents. However, it remains unclear whether there are differences in safety and efficacy between everolimus-eluting and sirolimus-eluting stents during long-term follow-up.

Methods and Results: Consecutive patients undergoing percutaneous coronary intervention with everolimus-eluting (n=1601) or sirolimus-eluting stents (n=1532) between May 2004 and March 2009 were identified. Using propensity score matching, we compared clinical outcome among 1342 pairs of patients treated with everolimus-eluting and sirolimus-eluting stents.
The primary outcome was a composite of death, myocardial infarction and target vessel revascularization. The median follow-up was 1.5 years and results are reported up to 3 years. Hazard ratios comparing everolimus-eluting and sirolimus-eluting stents were calculated using Cox regression analysis. The median duration of prescribed dual antiplatelet therapy was 12 months in both groups. The primary outcome occurred in 14.9% in the everolimus-eluting and 18.0% in the sirolimus-eluting stent group up to 3 years (hazard ratio 0.83, 95% CI 0.68-1.00, P=0.056).
All-cause mortality (6.0% versus 6.5%, P=0.59) was similar, whereas the risks of myocardial infarction (3.3% versus 5.0%, P=0.017), and target vessel revascularization (7.0% versus 9.6%, P=0.039) were lower with everolimus-eluting than sirolimus-eluting stents. Definite (hazard ratio 0.30, 95% interval 0.12-0.75, P=0.01) and definite or probable stent thrombosis (hazard ratio 0.64, 95% CI 0.41-0.98, P=0.041) were less frequent among patients treated with everolimus-eluting stents. The reduced rate of myocardial infarction with everolimus-eluting stents was explained in part by the lower risk of definite stent thrombosis and the corresponding decrease in events associated with stent thrombosis (hazard ratio 0.25, 95% CI 0.08 to 0.75, P=0.013).

Conclusions: The unrestricted use of everolimus-eluting stents appears to be associated with improved clinical long-term outcome compared with sirolimus-eluting stents. Differences in favour of the everolimus-eluting stent are driven in part by a lower risk of myocardial infarction associated with stent thrombosis.



Petr Widimsky, FESC
  Discussant
Discussant | see Presenter abstract Webcasts become available 24h after the presentation
Widimsky, Petr
(Czech Republic)
Open presentation slides

References


707005 - 707006

SessionTitle:

Hot Line II - Coronary artery disease
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.